May, 18 2017 12:36 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting

Results of Study of Lenvima (Lenvatinib) in Hepatocellular Carcinoma to Be Presented in Oral Session

TOKYO, May, 18 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima / Kisplyx, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, "eribulin"), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.

Detailed data regarding the results of a Phase III clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.

Major poster presentations will include a highlight of the results of a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and the results of a Phase I clinical trial of H3B-8800 in patients with advanced myeloid malignancies.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
April 19 2017 12:21 JST
 
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
April 11 2017 11:42 JST
 
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
April 05 2017 10:23 JST
 
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
April 05 2017 10:12 JST
 
Eisai to Launch Smell Identification Test UPSIT Series in Japan
April 04 2017 08:56 JST
 
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
March 29 2017 10:09 JST
 
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
March 29 2017 09:08 JST
 
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
January 25 2017 07:59 JST
 
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam
January 24 2017 17:43 JST
 
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
January 18 2017 13:23 JST
 
More Press release >>

Latest Press Release


More Latest Release >>